Kornimate/medical-research-clean huggingface dataset:
brain changes by rivastigmine according to butyrylcholinesterase alleles

Conditions: Alzheimer's Disease

Summary: butyrylcholinesterase (buche) activity is increasing in alzheimer disease (ad) process (lane et al., 2006). buche wild type has stronger butyrylcholine esterase activity than buche k variant allele and this strong activity can affect ad brain negatively by choline depletion. rivastigmine has unique dual action - acetylcholine esterase inhibition and butyrylcholine esterase inhibition. therefore, rivastigmine can lower serum butyrylcholine esterase activity and delay functional decrease of fluorodeoxyglucose positron emission tomography (fdg pet) images in ad patients with buche wild type allele by strong buche inhibition. it suggests that rivastigmine can affect brain function differently by buche genotype in ad. therefore, we will try to find the different changes of serum butyrylcholine esterase activity by elisa and functional and structural changes of brain between buche wild type and k-variant type by fdg pet and mri pre and post images after 12 month use of rivastigmine. 1. primary objective: 1. the mean changes of standardized uptake values (suvmean) in pet imaging 2. the mean changes of serum buche activity between buche wild type and k-variant type. 2. secondary objectives: 1. the mean changes of cortical thickness in brain mri 2. the cognitive changes in alzheimer's disease assessment scale-cognitive subscale (adas-cog) 3. the cognitive changes in mini-mental state exam (mmse) 4. the daily function changes by alzheimer's disease cooperative study - activities of daily living (adcs-adl) 5. the behavioural changes by caregiver-administered neuropsychiatric inventory (npi) 6. the disease severity changes by clinical dementia rating scale-sum of boxes (cdr-sb) between buche wild type and k-variant type.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease (nincd-adrda and mmse between 10 \~26) * who didn't take cholinesterase inhibitor on liver within 3 months exclusion criteria: * diagnosed with diseases other than ad that affect brain atrophy according to brain mri * diagnosed with diseases other than ad which affect cognitive functions (i.g. schizophrenia, major depression, mental retardation, encephalopathy, etc.) * didn't suspect of drug or alcohol addictions within last decade * unable to participate the study due to poor sight and hearing * who aren't suitable to participate according to the researchers' judgement

Keywords: rivastigmine, butyrylcholinesterase, mri, pet
effect of ergocalciferol on iron metabolism in individuals with chronic kidney disease

Conditions: CKD; Chronic Kidney Diseases; Hepcidin; Ergocalciferol; Vitamin D; Iron-deficiency; Anemia

Summary: the purpose of the study is to learn more about how treatment with vitamin d can affect iron metabolism and blood levels of hepcidin (hormone controlling iron levels) in people with chronic kidney disease (ckd). iron is an essential mineral which is a major component of proteins that carry oxygen in the blood. problems with iron metabolism can lead to low blood levels (anemia), which can commonly happen in people with ckd. new research over the last decade has uncovered a new hormone called 'hepcidin', which is made in the liver and released into the blood. hepcidin controls how much iron is in the blood by preventing the absorption of iron from food. blood levels of hepcidin c are found to be high in people with ckd, and a recent small study in people with normal kidney function showed that treatment with vitamin d decreased hepcidin levels. in this study, investigators would like to examine the effects of vitamin d (ergocalciferol) on iron metabolism and blood levels of hepcidin in individuals with ckd.


Eligibility criteria:
inclusion criteria: * participants 19 years or older with mild to moderate ckd (egfr 15 - 59 ml/min/1.73 m2) by the ckd-epi formula, with vitamin d deficiency (25(oh)d \ 100). exclusion criteria: * active vitamin d analog therapy or history of recent (\< 3 months) use. * nutritional vitamin d (cholecalciferol or ergocalciferol) therapy in dosages greater than 2000 iu/day. * subjects receiving erythropoiesis stimulating agents or intravenous iron therapy. * oral iron therapy started within the last 3 months. * hb \< 8.0 g/dl for males and hb \<7.0 g/dl for females. * pregnancy or lactation. * serum calcium \> 10.0 mg/dl or phosphorus \> 4.5 mg/dl. * subjects with acute kidney injury or rapidly declining gfr. * subjects on hemodialysis, peritoneal dialysis, or having a functioning renal transplant. * focus of active inflammation such as acute gout, rheumatoid arthritis or active infection determined clinically.
abdominal and lower extremity compression during tilt table testing in adolescent pots patients

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS); Syncope

Summary: postural orthostatic tachycardia syndrome (pots) is a common cause of orthostatic intolerance in adolescents and adults. compression stockings are commonly recommended as a treatment modality for pots, but the effects of abdominal and lower extremity compression during tilt table testing have not been measured in adolescent patients. the aims of our study are to compare heart-rate changes and symptom onset during tilt table testing (a) with and without abdomen/lower extremity compression and (b) with abdominal compression only versus lower extremity compression only. during phase 1, 20 adolescents with pots will undergo up to 10 minutes of tilt without compression (trial #1), a repeat study of up to 10 minutes with full compression (trial #2), and a third study without compression up to 10 minutes (trial #3). compression will be performed using the non-inflatable zoex anti-shock garment. during study phase 2, an additional 20 adolescent pots patients will undergo up to 10 minutes of tilt without compression (trial #1), a repeat study of up to 10 minutes with abdominal compression only \[n=10\] or lower extremity compression only \[n=10\] (trial #2), and a third study repeated without compression up to 10 minutes (trial #3). to limit compression to the abdomen only, we will use the zoex garment strap numbers 4 and 5 (thigh and abdomen) without straps 1-3 (lower extremities). for lower extremity-only compression, we will use zoex garment straps 1-4 (lower extremity and thigh) without strap 5. data collected will include mean and peak heart rates and timing of symptoms with each trial. a paired-samples t-test will be used to compare mean heart rates between trials for each study phase. hazard analyses will be used to assess time-based endpoints.


Eligibility criteria:
inclusion criteria: 1. age 12-19 years 2. pots diagnosis 3. english speaking - exclusion criteria: 1. somatic, cognitive, or psychiatric disorder that could prevent safe tilt table testing 2. medications that cannot be stopped/held safely for the procedure, but can cause or exacerbate orthostatic intolerance -

Keywords: pots orthostatic adolescent
spinal magnetic stimulation in neuropathic pain

Conditions: Neuropathic Pain

Summary: it involves delivering a train of magnetic pulses, 5 at each time, to the brain. in the present study, we are using the same method to treat severe pain due to nerve conditions. you will be given up to 1000 pulses in total over the spine in the lower back (spinal magnetic stimulation or sms). each train will be given in 10-second intervals. you will have sms on a single day. you will be given sms pulses at 1 or 10 per second. no stimulation will be given over the head. you will be assessed before and after the study for up to 1 week. your usual medical treatment will be continued

you must be aware of that this is a placebo-controlled trial. this means that you may either receive real sms or sham sms. the latter involves a harmless process of ineffective stimulation, designed for comparison with real sms. whether you receive either form of treatment will be assigned randomly, and there will be a 50% chance of being assigned to either.

Eligibility criteria:
inclusion criteria: * all with neuropathic lower limb pain exclusion criteria: * contraindications to magnetic stimulation

Keywords: magnetic stimulation neuropathic pain spinal lower limb clinical trial
clinical performance of toric hydrogel contact lenses following one week of daily wear

Conditions: Astigmatism

Summary: the aim of this prospective study is to evaluate the clinical performance of filcon iv1 toric and ocufilcon d toric contact lenses after 1 week of wear in each pair.

this is a 30-subject, prospective, randomized, double masked, bilateral, 1 week cross-over study comparing the fitting characteristics of filcon iv1 toric lenses against ocufilcon d hydrogel toric lenses.

Eligibility criteria:
inclusion criteria: * a person is eligible for inclusion in the study if he/she: * is between 18 and 40 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted soft toric contact lens wearer * has a contact lens spherical prescription between +6.00 to - 9.00 (inclusive) * have no less than -0.75d of astigmatism and no more than -2.00 d in both eyes. * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter. * patient contact lens refraction should fit within the available parameters of the study lenses. * is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so). * is willing to comply with the visit schedule exclusion criteria: * a person will be excluded from the study if he/she: * has a cl prescription outside the range of the available parameters of the study lenses. * has a spectacle cylinder less than -0.75d or more than -2.00 d of cylinder in either eye. * has a history of not achieving comfortable cl wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 (0.10 logmar) in either eye. * presence of clinically significant (grade 2-4) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear. confidential ex-mktg-66 clinical performance of toric hydrogel contact lenses following one week of daily wear 10 * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * giant papillary conjunctivitis (gcp) worse than grade 1 * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has presbyopia or has dependence on spectacles for near work over the contact lenses. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study.
ocular coherence tomography during cataract assessment

Conditions: Cataract Senile; Macula Hole; Epiretinal Membrane; Age Related Macular Degeneration; Vitreomacular Traction

Summary: many patients will have underlying maculopathy present when undergoing cataract surgery, which are not visible on fundoscopy alone. knowledge of this underlying pathology will allow an improved consenting process and discussion with the patient regarding the risks, visual prognosis and recovery following cataract surgery. incidental findings in the fellow eye would also allow for improved diagnosis and management of these patients without adding significant additional time to specialist high volume cataract assessment clinics.

the majority of anterior segment pathology may be diagnosed with simple slit lamp biomicroscopy, but posterior segment pathology may not be quite so obvious and can be missed on simple examination especially if a visually significant cataract is present impeding the view. there is also a degree of subjectivity from how much the cataract impairs the vision in comparison to the other elements of the optical pathway within the eye, and whilst there is no single way to evaluate this. optical coherence tomography (oct) has been widely present in ophthalmology clinics since it's development 20 years ago although it is not commonly used in all units for the pre-operative assessment of patients referred for cataract surgery in high volume set ups such as the national health service (nhs) in the united kingdom. there may still be reluctance to use oct in a normal cataract assessment clinic as it may be perceived as an additional step that decreases time efficiency and increase financial investment in the services. in this study we sought to investigate the prevalence of retinal pathology in the patient cohort, the comparison of subjective clinical slit lamp fundoscopy assessmenet with oct findings and the co-incidental oct findings in the fellow eye at the time of cataract assessment. oct was chosen as the most efficient way to support clinicians in the assessment clinics, and to see if the addition of this step added value to the patient consultation and pre-operative assessment.

Eligibility criteria:
inclusion criteria: * patients referred for cataract surgery exclusion criteria: * patients unable to attend the cataract assessment clinic * morbid patients who cannot be assessed on oct or slit lamp

Keywords: cataract, macular pathology, ocular coherence tomography
adrenal suppression and pharmacokinetics of topicort® spray, 0.25% in pediatric patients with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the objective of this study is to evaluate the potential of topicort® (desoximetasone) topical spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. the secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.

an open label, post marketing safety study to assess the potential of a topicort® (desoximetasone) topical spray, 0.25% to suppress hpa axis function following twice daily dosing for 28 days.

Eligibility criteria:
inclusion criteria: * patients aged 7 years and older must have provided written assent accompanied by written informed consent from patient's representative * clinical diagnosis of stable plaque psoriasis with involvement of ≥ 10% body surface area (excluding face and scalp) * physicians global assessment score of 3 or 4 at baseline exclusion criteria: * has other dermatological conditions that may interfere with clinical assessments * allergy or sensitivity to corticosteroids or any drug hypersensitivity or intolerance that would compromise patient safety or study results * history of an adverse reaction to cortrosyn™ or similar test reagents * chronic infectious disease, system or organ disorder or other medical condition that would place patient at undue risk by study participation
neonatal outcome of children with antenatal colic hyperechogenicity

Conditions: Colic; Nephropathy

Summary: fetal colic hyper-echogenicity is a presenting symptoms for cystinuria lysinuria. a few cases of fetuses with dibasic protein intolerance (more complex prognosis) presented with colic hyper-echogenicity antenatal. the aim of this retrospective study is to assess the outcome of fetuses with colic hyperechogenicity in order to increase prenatal counseling

observational multicenter retrospective study from january 2011 to january 2021. no supplementary visit, directly related to the research, will be necessary. this study does not change the usual management of the patient. patients will be included after their usual medical check-up.

Eligibility criteria:
inclusion criteria: * fetuses with prenatal colic hyperechogenicity * between january 2011 and january 2021 * born without term limitation. exclusion criteria: * intestinal hyperechogenicity * polymalformative syndrome * patients age\<15 years

Keywords: gynecology-obstetrics ultrasound medical genetics pediatrics nephropathy colic hyperechogenicity antenatal lysinuria-cystinuria lysinuric protein intolerance
prospective comparative multicenter study of the care pathway after shoulder surgery

Conditions: Shoulder Injury

Summary: post-operative management of shoulder surgery patients, particularly in terms of pain management and follow-up, can vary from one center to another, influencing clinical outcomes and patient satisfaction. the aim of this study is to compare two approaches to post-operative follow-up in two distinct centers: structured follow-up using the vivalto-dom protocol in paris, and autonomous follow-up through contact with a nurse in saint-grégoire. the hypothesis is that these differences in the care pathway will affect pain management, comfort and patient satisfaction. by controlling for operative variability (a single surgeon operating in both centers), the study will identify the most effective follow-up practices for improving post-operative management, with the ultimate aim of optimizing quality of care and reducing post-operative complications.


Eligibility criteria:
inclusion criteria: * patient eligible for one of the following 4 types of surgery: simple non-repair arthroscopic surgery (acromion, calcification), arthroscopic repair surgery (cuff, das, bankart), open surgery without prosthesis (ligamentoplasty, bone block), open surgery with prosthesis (inverted prosthesis, anatomic prosthesis, etc.). exclusion criteria: * patients with one or more communication disorders. * pregnant or breast-feeding patients * patients not covered by a social security scheme * refusal to participate in research * patients unable to understand or give informed consent * patients under guardianship, deprived of liberty or under court protection * patients with past or present drug addiction * patients with neuropathy * patients with cognitive disorders * patients with chronic illnesses or inflammatory pathologies leading to chronic pain.

Keywords: shoulder surgery pain comfort
inflammatory markers in obstructive sleep apnea (osa) patients.

Conditions: Obstructive Sleep Apnea of Adult

Summary: the aim of our study was to assess the levels of inflammatory biomarkers in a large sample of osa patients and to investigate any correlation between these markers with clinical and polysomnographic (psg) parameters. subjects undergone a psg for osa diagnosis were recruited. patients with known comorbidities were excluded from the study. included patients were grouped according to apnea-hypopnea index (ahi) as mild, moderate and severe. patients with ahi \< 5 served as control group. demographic, psg data, serum levels of hs-c-reactive protein (hs-crp), fibrinogen, erythrocyte sedimentation rate (esr) and uric acid (ua) were measured and compared between groups.

systemic inflammation is important in obstructive sleep apnea (osa) pathophysiology and its comorbidity. the objective of this study was to investigate how early biomarkers of inflammation may be altered in osa patients. to complete this goal the investigators assessed the circulating levels of four inflammatory markers, hs-c-reactive protein (hs-crp), fibrinogen, erythrocyte sedimentation rate (esr) and uric acid (ua) in a representative population of consecutively enrolled, untreated and otherwise healthy subjects with a clinical suspicion of obstructive sleep apnea. a secondary objective was to investigate any correlation between these markers with clinical and polysomnographic (psg) parameters of these subjects.subjects who had undergone a psg for osa diagnosis were recruited. patients with known comorbidities were excluded from the study. included patients were grouped according to apnea-hypopnea index (ahi) as mild, moderate and severe. patients with ahi \< 5 served as control group. demographic, psg data, serum levels of hs-crp, fibrinogen, esr and ua were measured and compared between groups.

Eligibility criteria:
inclusion criteria: * newly diagnosed, untreated, and otherwise healthy obstructive sleep apnea (osa) patients * healthy subjects (without osa) exclusion criteria: * refusal to participate, * previous osa diagnosis and treatment * known comorbidities, * pregnancy, * history of narcolepsy or restless leg syndrome. * subjects younger than 18 years, * central sleep apnea syndrome (csas) diagnosed with psg,
evaluate the lightening effect of the whitening cosmetic product bex-2011

Conditions: Solar Lentigines

Summary: background: solar lentigines are a common dermatologic condition that manifest as circumscribed single or multiple brownish macules usually located on sun-exposed skin such as face, hands or forearms. an effective, safe, daily-use, homecare whitening product may alleviate the cosmetic concerns for the general population. the efficacy and safety of the previous generation bex-2009 (blanc expert spot eraser, l'oreal, france), a whitening cosmetic product containing ellagic acid, salicylic acid, licorice root extract, etc., has been established in caucasian and asian populations with facial solar lentigines. objective: the purpose of this placebo-controlled, single-center study is 1) to evaluate the efficacy of the new generation whitening cosmetic product bex-2011 (ultimate whitening spot eraser, l'oreal, france) in the improvement of solar lentigines on the dorsum of hands or forearms, and 2) to evaluate the efficacy of bex-2011 by harmonic generation microscopy to obtain information of the epidermal melanin continuum, compared to other standard tools for melanin measurement.

method: 40 subjects, who are non-gravid women between 45 to 65 years old and need to have ≥10 solar lentigines on the forearms/hands, will be recruited. one to three flat lesions which are larger than 4 mm and with the same pigmentation intensity on the left or right forearm/hand, respectively, are designated the target lesions. however, all lesions on the randomly selected side will be treated with bex-2011 twice a day. the opposite site will be treated with vehicle and is served as the control. evaluation will be performed at week 0, 4 and 8. at each visit, treated and control spots as well as their surrounding spotless skin will be evaluated using pigmentation index scores, visia-cr, siascope, dermascore, and harmonic generation microscopy. evaluation of the efficacy of whitening will be compared to the baseline and to the control area between week 0 and week 8. safety will be assessed using clinical monitoring and adverse event reporting.

Eligibility criteria:
inclusion criteria: * 40-65 years old asian women (skin types iii to iv) * with ≥10 solar lentigines on the forearms or dorsum of hands * with at least one to three lesions ≥4 mm on the left or right forearm/ dorsum of hand, respectively, which are flat and are at the same pigmentation degree according to the color chart. exclusion criteria: * having major treatment, including topical hydroquinone or tretinoin, cryotherapy, electrosurgery, trichloroacetic acid application, laser or intense pulsed light, in the 3 months before the beginning of the study * past history of allergy to whitening cosmetic products * past history of atopic dermatitis * habit of going to the tanning salon or frequent sun exposure longer than 4 hours per day